Abstract The purpose of this study was to quantify the frequency of Mycoplasma pneumoniae or Chlamydia pneumoniae in a large contemporary real-world data set. This was a retrospective database analysis utilizing data collected from the TriNetX Global Collaborative Network, which provided access to electronic medical records for patients from 78 different healthcare organizations. Data were collected using ICD-10 codes and laboratory test order codes from TriNetX. Inclusion criteria are patients less than or equal to 18 years old with SCD with an ICD-10 code for ACS or pneumonia. Patients were included in the primary outcome analysis if they had a laboratory code for a rapid diagnostic test for M. pneumoniae and/or C. pneumoniae performed by either nasal swab or respiratory culture. There were 6762 pediatric sickle cell patients with an ICD-10 code for ACS or pneumonia identified. Of these patients, only 16.3% were tested for M. pneumoniae and 17.1% were tested for C. pneumoniae. The patients who were tested for these atypical organisms were further investigated for positivity on rapid diagnostic testing, and the positivity rate in these patients was 1.1% for M. pneumoniae and less than or equal to 0.87% for C. pneumoniae. Pediatric patients with ACS who were tested for M. pnuemoniae and C. pnuemoniae had low rates of positivity for these organisms. Most of these patients did not have recorded microbiologic testing, showing evidence of a large underutilization of diagnostic tools available that could assist with de-escalation of antibiotics.
Read full abstract